Doctors review new drug Combo's Real-World fight against lung cancer
NCT ID NCT07141563
Summary
This study looked back at medical records to see how well a combination of immunotherapy (nivolumab) and chemotherapy worked for Argentinian patients with early-stage, operable lung cancer. The goal was to see if this treatment given before surgery could completely eliminate the cancer. Researchers reviewed data from about 70 patients who received this treatment between 2022 and 2025.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Grupo Argentino Oncología Torácica (GAOT) - Asociación Argentina Oncología Clínica (AAOC)
Buenos Aires, C1426CPU, Argentina
Conditions
Explore the condition pages connected to this study.